Argininosuccinate Synthase 1 is a Metabolic Regulator of Colorectal Cancer Pathogenicity
Authors:
- Wan-Min KuWKWan-Min Ku
- Christine F. SkibolaCSChristine F. Skibola
- Daniel K. NomuraDNDaniel K. Nomura
- 1 March 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 12 (4) , 905-911
Abstract
Like many cancer types, colorectal cancers have dysregulated metabolism that promotes their pathogenic features. In this study, we used the activity-based protein profiling chemoproteomic platform to profile cysteine-reactive metabolic enzymes that are upregulated in primary human colorectal tumors. We identified argininosuccinate synthase 1 (ASS1) as an upregulated target in primary human colorectal tumors and show that pharmacological inhibition or genetic ablation of ASS1 impairs colorectal cancer pathogenicity. Using metabolomic profiling, we show that ASS1 inhibition leads to reductions in the levels of oncogenic metabolite fumarate, leading to impairments in glycolytic metabolism that supports colorectal cancer cell pathogenicity. We show here that ASS1 inhibitors may represent a novel therapeutic approach for attenuating colorectal cancer through compromising critical metabolic and metabolite signaling pathways and demonstrate the utility of coupling chemoproteomic and metabolomic strategies to map novel metabolic regulators of cancer.Keywords
Funding Information
- National Cancer Institute (R01 CA172667)
- Congressionally Directed Medical Research Programs (W81XWH-15-1-0050)
- American Cancer Society (RSG14-242-01-TBE)
This publication has 33 references indexed in Scilit:
- ASS1as a Novel Tumor Suppressor Gene in Myxofibrosarcomas: Aberrant Loss via Epigenetic DNA Methylation Confers Aggressive Phenotypes, Negative Prognostic Impact, and Therapeutic RelevanceClinical Cancer Research, 2013
- NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sinkNature Chemical Biology, 2013
- Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALLNature Medicine, 2013
- Quantitative reactivity profiling predicts functional cysteines in proteomesNature, 2010
- Activity-based protein profiling for biochemical pathway discovery in cancerNature Reviews Cancer, 2010
- Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancerInternational Journal of Cancer, 2010
- Reduced Argininosuccinate Synthetase Is a Predictive Biomarker for the Development of Pulmonary Metastasis in Patients with OsteosarcomaMolecular Cancer Therapeutics, 2010
- Proteomic Expression Analysis of Surgical Human Colorectal Cancer Tissues: Up-Regulation of PSB7, PRDX1, and SRP9 and Hypoxic Adaptation in CancerJournal of Proteome Research, 2008
- Fatty acid synthase and the lipogenic phenotype in cancer pathogenesisNature Reviews Cancer, 2007
- Tandem orthogonal proteolysis-activity-based protein profiling (TOP-ABPP)—a general method for mapping sites of probe modification in proteomesNature Protocols, 2007